436 related articles for article (PubMed ID: 21670078)
1. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy.
Rountree RB; Mandl SJ; Nachtwey JM; Dalpozzo K; Do L; Lombardo JR; Schoonmaker PL; Brinkmann K; Dirmeier U; Laus R; Delcayre A
Cancer Res; 2011 Aug; 71(15):5235-44. PubMed ID: 21670078
[TBL] [Abstract][Full Text] [Related]
2. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
3. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
Hwang C; Sanda MG
Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
[TBL] [Abstract][Full Text] [Related]
4. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
[TBL] [Abstract][Full Text] [Related]
5. Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses.
Zeelenberg IS; Ostrowski M; Krumeich S; Bobrie A; Jancic C; Boissonnas A; Delcayre A; Le Pecq JB; Combadière B; Amigorena S; Théry C
Cancer Res; 2008 Feb; 68(4):1228-35. PubMed ID: 18281500
[TBL] [Abstract][Full Text] [Related]
6. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
Gulley J; Chen AP; Dahut W; Arlen PM; Bastian A; Steinberg SM; Tsang K; Panicali D; Poole D; Schlom J; Michael Hamilton J
Prostate; 2002 Oct; 53(2):109-17. PubMed ID: 12242725
[TBL] [Abstract][Full Text] [Related]
8. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
[TBL] [Abstract][Full Text] [Related]
9. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245
[TBL] [Abstract][Full Text] [Related]
11. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
[TBL] [Abstract][Full Text] [Related]
12. Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer.
McNeel DG; Nguyen LD; Ellis WJ; Higano CS; Lange PH; Disis ML
Prostate; 2001 May; 47(3):222-9. PubMed ID: 11351352
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.
Simons JW; Carducci MA; Mikhak B; Lim M; Biedrzycki B; Borellini F; Clift SM; Hege KM; Ando DG; Piantadosi S; Mulligan R; Nelson WG
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3394-401. PubMed ID: 16740763
[TBL] [Abstract][Full Text] [Related]
14. Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.
Saif JM; Vadakekolathu J; Rane SS; McDonald D; Ahmad M; Mathieu M; Pockley AG; Durrant L; Metheringham R; Rees RC; McArdle SE
Eur J Immunol; 2014 Apr; 44(4):994-1004. PubMed ID: 24338683
[TBL] [Abstract][Full Text] [Related]
15. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
Garcia-Hernandez Mde L; Gray A; Hubby B; Kast WM
Cancer Res; 2007 Feb; 67(3):1344-51. PubMed ID: 17283172
[TBL] [Abstract][Full Text] [Related]
16. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
Lubaroff DM; Karan D
Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
[TBL] [Abstract][Full Text] [Related]
17. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
18. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
[TBL] [Abstract][Full Text] [Related]
19. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine.
Kim JJ; Trivedi NN; Wilson DM; Mahalingam S; Morrison L; Tsai A; Chattergoon MA; Dang K; Patel M; Ahn L; Boyer JD; Chalian AA; Schoemaker H; Kieber-Emmons T; Agadjanyan MA; Weiner DB
Oncogene; 1998 Dec; 17(24):3125-35. PubMed ID: 9872328
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.
Reinartz S; Hombach A; Köhler S; Schlebusch H; Wallwiener D; Abken H; Wagner U
Cancer Res; 2003 Jun; 63(12):3234-40. PubMed ID: 12810653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]